TechnipFMC plc Ordinary Share vs Recursion Pharmaceuticals Inc — how do they compare? TechnipFMC plc Ordinary Share trades at $69.63 (market cap $26.82B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: TechnipFMC plc Ordinary Share is far larger — about 11.6× Recursion Pharmaceuticals Inc's market cap, and TechnipFMC plc Ordinary Share pays a 0.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FTI | RXRX | |
|---|---|---|
Market Cap | $26.82B | $2.31B |
Volume | 2,469,689 | 40,478,768 |
Sector | Energy | Health |
52-Week High | $80.08 | $6.79 |
52-Week Low | $35.57 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $27.07B | $1.83B |
Dividend Yield | 0.29% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →